Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence". Mazza MG, Vai B, De Picker L, Benedetti F, et al. Drugs 2022;82:349-351.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mazza MG, Vai B, De Picker L, Benedetti F, et al. Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence". Drugs 2022;82:349-351.
PMID: 35150437